Clobazam add-on therapy for drug-resistant epilepsy

Bresnahan, Rebecca; Martin‐McGill, Kirsty J; Williamson, John; Michael, Benedict; Marson, Anthony G

doi:10.1002/14651858.cd004154.pub5

Cited by 11 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Still, the data regarding its efficacy are rather limited. A recent Cochrane review based on four small randomized trials concluded that it may be effective as add-on therapy in epilepsy, but the evidence is of very low quality [25]. Similarly, few small-cohort observational studies have also reported its effectiveness as a first add-on ASM in patients with drug-resistant epilepsy [10,12,24].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience

Satishchandra

Rathore²,

Apte³

et al. 2022

Epilepsy & Behavior

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience

Satishchandra

Rathore²,

Apte³

et al. 2022

Epilepsy & Behavior

View full text Add to dashboard Cite

“…Collectively, 27 out of 175 patients were seizure-free during treatment with clobazam (3 RCTs, n = 175, very low-quality evidence). There was a slightly higher incidence of treatment withdrawal associated with receiving clobazam, although the overall incidence was still fairly low (4 RCTs, n = 197, very low quality evidence) [15].…”

Section: Pharmacological Treatmentmentioning

confidence: 98%

“…Despite the effectiveness of vigabatrin, its longterm use is associated with visual field constrictions which occur in a significant number of people taking vigabatrin. Given the seriousness of such visual adverse effects, the implications of long-term vigabatrin use should still be considered before commencing vigabatrin add-on therapy [15,16,17,18,19,20]. Finally, neurosteroids are compounds possessing the ability to modulate neuronal activity and affect the physiology of the central nervous system (CNS).…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Epilepsy in childhood: an update on management

Costa¹,

Silva²,

Thomazin³

et al. 2023

Arch Pediat Neurosurg

View full text Add to dashboard Cite

Background: The aim of this study was to review current database for the management of childhood epilepsy, presenting and comparing the different types of treatment, focusing[1] on the ones with the best efficacy. Original articles related to the subject were obtained from SciELO, PubMed and BVS database using descriptors from “Health Sciences Descriptors”. Results: Epilepsy is characterized as a neurological disease that occurs due to abnormal neuronal discharges in the cerebral cortex. It affects 0.5% to 1% of children and is the most frequent chronic neurologic condition in childhood. Anti-epileptic drugs (AEDs) are the most used treatment for epilepsy. Non farmacological options, such as epilepsy surgery and neurostimulation therapy can be used to treat refractory or drug-resistant seizures. Conclusions: Around 70% of individuals with active epilepsy can become seizure-free and go into long-term remission shortly after starting drug treatment with antiepileptic drug in monotherapy. Randomized controlled trials comparing surgery and combinations of AEDs suggest that surgery can be more effective in stopping seizures in children.

show abstract

“…Data on FLB in focal epilepsies are not conclusive but do not seem to support its use in this context [42]. Evidence on CLB is still limited but a small trial on 197 patients seems promising [43].…”

Section: Adjunctive Treatmentmentioning

confidence: 99%

Pharmacological treatment of focal epilepsy in adults: an evidence based approach

Mula

2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction:Focal seizures represent the most common seizure type and focal epilepsies the most common epilepsy type. Anti-seizure medications (ASMs) still represent the main form of treatment for epilepsy. Areas covered:The aim of this review article is to provide an overview of available evidence about current and upcoming pharmacological options and strategies for adults with focal epilepsy focusing on the last 5 years.Expert opinion: Seventeen drugs are currently approved for the treatment of focal seizures including cenobamate as the very latest option. Ten of these drugs are also licensed for monotherapy. Level A evidence for initial monotherapy is available for seven drugs with no robust data supporting that one drug is superior to the other. Safety, tolerability as well as pharmacoeconomic reasons would then drive treatment decisions. Data on adjunctive treatment are available for 13 ASMs showing again no obvious difference in terms of efficacy. Evidence on specific drug combinations is almost non-existent and the final decision of combining specific drugs is based on the experience of the individual clinician rather than on robust evidence. Current outcome measures do not consider number of previously failed drugs and the observation period is often too short.

show abstract

Clobazam add-on therapy for drug-resistant epilepsy

Cited by 11 publications

References 22 publications

Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience

Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience

Epilepsy in childhood: an update on management

Pharmacological treatment of focal epilepsy in adults: an evidence based approach

Contact Info

Product

Resources

About